<DOC>
	<DOCNO>NCT00210327</DOCNO>
	<brief_summary>The primary objective study assess antitumor activity ( term overall response rate - ORR - i.e . sum complete partial response ) bortezomib pretreated MALT lymphomas one prior sistemic therapy regimen</brief_summary>
	<brief_title>VELCADE MALT Lymphoma Pretreated With Prior Systemic Therapy</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>1. histologically proven MALT lymphoma extranodal site 2. stage ( Ann Arbor IIV ) 3. relapsed refractory disease pretreated prior chemotherapy regimen +/ antiCD20 immunotherapy prior antiCD20 immunotherapy ( number prior line therapy ) 4. evidence histologic transformation high grade lymphoma 5. measurable evaluable disease 6. age &gt; 18 year 7. full recovery previous therapy , life expectancy least 6 month 8 . ECOG performance status 02 9. primary gastric localize H. pyloripositive disease diagnosis : 1. persistent disease 1 year document H. pylori infection eradication 2. clinical , endoscopic ( histologic ) evidence progression time H. pylorus infection eradication 10. prior chemotherapy , immunotherapy radiotherapy last 6 week 11. corticosteroid last 4 week , unless prednisone chronically administer dose &lt; 20 mg/day indication lymphoma lymphomarelated symptom 12. adequate renal function ( calculate measure creatinine clearance &gt; 30 mL/minute ) , liver function ( ASAT/ALAT &lt; 2,5 upper normal , total bilirubin &lt; 2,5x upper normal ) bone marrow function 13. evidence active opportunistic infection 14. know HIV infection 15. active HBV and/or HCV infection 16. serious medical illness likely interfere participation clinical study 17. voluntary write informed consent performance studyrelated procedure 18. female subject either postmenopausal surgically sterilize willing use acceptable method birth control ( ie , hormonal contraceptive , intrauterine device , diaphragm spermicide , condom spermicide , abstinence ) duration study . Male subject agrees use acceptable method contraception duration study 1. prior diagnosis neoplasm within 5 year , except cervical intraepithelial neoplasia type 1 ( CIN1 ) localize nonmelanomatous skin cancer 2. investigational drug within 14 day enrollment 3. evidence symptomatic central nervous system ( CNS ) disease 4. severe impairment bone marrow function ( ANC &lt; 1.0x109/L , PLT &lt; 30x109/L within 14 day enrollment ) , unless due lymphoma involvement 5. evidence â‰¥ grade 2 peripheral neuropathy within 14 day enrollment 6. know hypersensitivity bortezomib , boron mannitol 7. pregnant lactating status , confirmation subject pregnant must establish negative serum betahuman chorionic gonadotropin ( betahCG ) pregnancy test result obtain screening . Pregnancy test require postmenopausal surgically sterilize woman 8. psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule ; condition discuss patient registration trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
</DOC>